Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Were Right About Kythera Biopharmaceuticals Inc (KYTH), Rewarded with 48% Gains

Our hedge fund indicator was right about Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) when it issued a buy signal based on recent activity. The number of bullish hedge fund bets in KYTH rose by 6 during the first quarter. KYTH was in 23 hedge funds’ portfolio at the end of March. There were 17 hedge funds in our database with KYTH holdings at the end of the previous quarter.

To the average investor there are a multitude of metrics stock market investors employ to assess their stock investments. A couple of the less utilized metrics are hedge fund and insider trading activity. Our research have shown that, historically, those who follow the top picks of the elite investment managers can trounce the market by a very impressive amount (see the details here). The 15 most popular small-cap stocks among hedge funds outperformed the market by double digits annually in our back tests. The performance of these stocks were even better since we started tracking them in real-time. Since the end of August 2012 these stocks beat the S&P 500 Index by nearly 20 percentage points per year.

Allergan Plc (NYSE:AGN) and Kythera Biopaharmaceuticals announced today that Allergan will acquire Kythera for $75 a share in a cash and stock transaction. The stock was trading at $50 just at the end of March. Hedge funds made 48% in 2.5 months. Let’s take a glance at the latest action surrounding Kythera Biopharmaceuticals Inc (NASDAQ:KYTH).

How have hedgies been trading Kythera Biopharmaceuticals Inc (NASDAQ:KYTH)?

Heading into Q2, a total of 23 of the hedge funds tracked by Insider Monkey were long in this stock, a change of 35% from the previous quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of notable hedge fund managers who were boosting their holdings considerably.

Of the funds tracked by Insider Monkey, William Leland Edwards’s Palo Alto Investors had the largest position in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH), worth close to $69.3 million, amounting to 3.4% of its total 13F portfolio. On Palo Alto Investors’s heels is Partner Fund Management, managed by Christopher Medlock James, which held a $62.3 million position; 1.7% of its 13F portfolio is allocated to the company. Remaining hedgies that hold long positions include Samuel Isaly’s OrbiMed Advisors, Roberto Mignone’s Bridger Management and Arthur B Cohen and Joseph Healey’s Healthcor Management LP.

As aggregate interest increased, key money managers have jumped into Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) headfirst. Bridger Management, managed by Roberto Mignone, initiated the biggest position in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH). Bridger Management had 22.3 million invested in the company at the end of the quarter. Jeremy Green’s Redmile Group also made a $11.3 million investment in the stock during the quarter. The other funds with new positions in the stock are Israel Englander’s Millennium Management, Kris Jenner, Gordon Bussard, Graham McPhail’s Rock Springs Capital Management, and Curtis Schenker and Craig Effron’s Scoggin.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!